TERRA
发表于 2025-3-30 11:04:12
Human Melanoma Associated Antigens Identified with Monoclonal Antibodies: Characterization and Potenigens referred to as melanoma associated antigens (MAA), have been identified with cell mediated immunity assays and with serological assays (for review, see 1,2). In the latter for many years the source of antibodies have been sera from patients with melanoma and sera from animals immunized with MA
anatomical
发表于 2025-3-30 14:19:32
http://reply.papertrans.cn/25/2417/241675/241675_52.png
细胞膜
发表于 2025-3-30 19:20:43
Immune Responses to Human Malignant Melanomat tumors of this type may be immunogenic and may provoke immune responses in the tumor bearing host. Host control of tumor growth is best illustrated clinically by cases of spontaneous regression of tumors. Spontaneous regression is defined as the complete disappearance or the reduction in size of h
肿块
发表于 2025-3-31 00:31:05
http://reply.papertrans.cn/25/2417/241675/241675_54.png
呼吸
发表于 2025-3-31 03:45:15
http://reply.papertrans.cn/25/2417/241675/241675_55.png
anaerobic
发表于 2025-3-31 07:40:12
Prognostic Factors for Cutaneous Melanomainical and histopathologic features of primary tumors. Observations of biologic behavior seem to be generalizable over wide geographic areas. For example, tumor behavior in Australia appears to be similar to that observed in the United States which in turn appears to be similar to that observed for
Decrepit
发表于 2025-3-31 11:02:48
http://reply.papertrans.cn/25/2417/241675/241675_57.png
勉励
发表于 2025-3-31 14:36:12
http://reply.papertrans.cn/25/2417/241675/241675_58.png
尖叫
发表于 2025-3-31 18:26:53
Local Excision and Regional Perfusion in High-Risk Stage-I Malignant Melanoma of the Extremitiesases. In recent years studies by Clark et al. (7) and Breslow (4) have revealed several additional clinical and histologic characteristics of the primary tumor to which prognostic significance can be ascribed. Tumor size, depth of invasion, ulceration, vascular invasion, and lymphoid reaction along
热心
发表于 2025-3-31 22:51:52
The Use of Chemotherapy in the Management of Patients with Malignant Melanoma response rates are between 20 and 30%. Most of the responding patients in these trials have partial remissions and often the difference between the mean survivals of responding and non-responding patients is 4 months at most. Even this difference may not indicate that there is a real benefit in ter